A retrospective study of GLP-1 receptor agonists uses in the management of hidradenitis suppurativa
DOI:
https://doi.org/10.18203/issn.2455-4529.IntJResDermatol20262836Keywords:
Hidradenitis suppurativa, GLP-1RA, Glucagon-like peptide receptor agonist, Metabolic disordersAbstract
Background: Hidradenitis suppurativa (HS) is a chronic inflammatory disorder frequently associated with metabolic comorbidities. Given the anti-inflammatory and metabolic effects of GLP-receptor agonists (GLP-1Ras), these agents have been proposed as a potential adjunctive therapy for HS.
Methods: A retrospective chart review identified 151 HS patients prescribed a GLP-1RA between January 2020 and January 2025. After excluding individuals younger than 18 years and those initiating biologics, long-term immunomodulators, or anti-hormonal therapies after GLP-1RA start, 22 patients met inclusion criteria. Clinical improvement was assessed qualitatively through provider documentation of symptom or disease-status improvement.
Results: Among 22 patients, 63.6% demonstrated clinical improvement following GLP-1RA therapy. The cohort included 10 Black, 6 Hispanic, 5 White, and 1 Asian patient. Semaglutide was the most common agent (n=14), followed by tirzepatide (n=7), and exenatide (n=1). Race was significantly associated with improvement (p= 0.025). 92% of non-Black patients improved compared with 30% of Black patients (p= 0.011). This disparity persisted after adjusting for HS severity, treatment duration, comorbidities, insurance type, and income. No significant associations were observed for gender, age, ethnicity, comorbidities, or insurance type.
Conclusions: GLP-1RAs may offer symptomatic benefit for HS, with nearly two-thirds of patients showing improvement. However, marked racial differences in response highlight the need for equitable HS research and investigation into biological, structural, and socioeconomic contributors to treatment variability. Larger prospective studies are warranted to clarify therapeutic efficacy and drivers of demographic disparities.
References
Krajewski PK, Złotowska A, Szepietowski JC. The Therapeutic Potential of GLP-1 Receptor Agonists in the Management of Hidradenitis Suppurativa: A Systematic Review of Anti-Inflammatory and Metabolic Effects. J Clin Med. 2024;13(21):6292.
Lyons D, Louly Nathan A, Pender E, Murray G, Smith C, Kirby B, et al. Semaglutide for weight loss in people with obesity as an adjunctive treatment for hidradenitis suppurativa: its impact on disease control and quality of life. Br J Dermatol. 2024;191(4):631-3. DOI: https://doi.org/10.1093/bjd/ljae216
Jennings L, Nestor L, Molloy O, Hughes R, Moriarty B, Kirby B. The treatment of hidradenitis suppurativa with the glucagon-like peptide-1 agonist liraglutide. Br J Dermatol. 2017;177(3):858-9. DOI: https://doi.org/10.1111/bjd.15233
Karacabeyli D, Lacaille D. Glucagon-Like Peptide 1 Receptor Agonists in Patients With Inflammatory Arthritis or Psoriasis: A Scoping Review. J Clin Rheumatol. 2024;30(1):26-31. DOI: https://doi.org/10.1097/RHU.0000000000001949
Gouvrion L, Delage M, Villani AP, Le Naour S, Fite C, Cassius C, et al; IGDO (Institut de Dermatologie du Grand-Ouest); HS-France group of the French Society of Dermatology. Glucagon-Like Peptide-1 Receptor Agonists in Hidradenitis Suppurativa. JAMA Dermatol. 2025;161(10):1084-6.
Gouvrion L, Delage M, Villani AP, Le Naour S, Fite C, Cassius C, et al; IGDO (Institut de Dermatologie du Grand-Ouest); HS-France group of the French Society of Dermatology. Glucagon-Like Peptide-1 Receptor Agonists in Hidradenitis Suppurativa. JAMA Dermatol. 2025;161(10):1084-6. DOI: https://doi.org/10.1001/jamadermatol.2025.2723
Krajewski PK, Złotowska A, Szepietowski JC. The Therapeutic Potential of GLP-1 Receptor Agonists in the Management of Hidradenitis Suppurativa: A Systematic Review of Anti-Inflammatory and Metabolic Effects. J Clin Med. 2024;13(21):6292. DOI: https://doi.org/10.3390/jcm13216292
Almukhadeb E, Nagshabandi KN, Alshehri N, Alosaimi K, Almusa HA, Almudimeegh A. Glucagon-Like Peptide-1 Receptor Agonists as Adjunctive Therapy for Hidradenitis Suppurativa in Patients With Overweight/Obesity: A Narrative Review of Efficacy, Safety, and Quality-of-Life Outcomes. Int J Dermatol. 2026;65(6):1168-75. DOI: https://doi.org/10.1111/ijd.70346
Ngabea MA, Dimeji IY. GLP-1 receptor agonists and inflammatory pathway modulation: Dual targeting of metabolic and immune dysfunction in insulin resistance. Biochem Biophys Res Commun. 2025;789:152822. DOI: https://doi.org/10.1016/j.bbrc.2025.152822
Sabat R, Alavi A, Wolk K, Wortsman X, McGrath B, Garg A, et al. Hidradenitis suppurativa. Lancet. 2025;405(10476):420-38. DOI: https://doi.org/10.1016/S0140-6736(24)02475-9
Dimitrion PM, Krevh R, Veenstra J, Ge J, Siddiqui A, Ferguson D, et al. High-throughput proteomics identifies inflammatory proteins associated with disease severity and genetic ancestry in patients with hidradenitis suppurativa. Br J Dermatol. 2025;192(6):1063-71. DOI: https://doi.org/10.1093/bjd/ljaf012
Ulschmid C, Serrano L, Wu R, Roth GM, Sokumbi O. African American race is a risk factor for severe hidradenitis suppurativa. Int J Dermatol. 2023;62(5):657-63. DOI: https://doi.org/10.1111/ijd.16428
Chang AY, Sanchez-Anguiano ME, Supapannachart K, Amerson EH, Naik HB, Shiboski S, et al. Neighborhood Socioeconomic Status and New Hidradenitis Suppurativa Diagnoses in a Single Health System. JAMA Dermatol. 2025;161(7):707-14. DOI: https://doi.org/10.1001/jamadermatol.2025.1190
Gupta AK, Economopoulos V, Mirmirani P, Magalhaes R. Understanding the evolving treatment landscape of hidradenitis suppurativa: An analysis of All of Us. PLoS One. 2025;20(8):e0331032. DOI: https://doi.org/10.1371/journal.pone.0331032
Downloads
Published
How to Cite
Issue
Section
